Pharmaceuticals News and Research

RSS

NPS MedicineWise finds little or no clinical benefit in switching to rivaroxaban for stroke prevention

With oral anticoagulant rivaroxaban set to be subsidised under the Pharmaceutical Benefits Scheme (PBS) for preventing stroke, NPS MedicineWise is urging people to talk to their doctor before stopping or making any changes to their anticoagulant medicines.

30 Jul 2013

FDA grants orphan-drug designation to Convergence's CNV1014802 for treatment of TN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, is pleased to announce that its novel sodium channel blocker, CNV1014802 ('802), has been granted orphan-drug designation by the US Food and Drug Administration for the treatment of trigeminal neuralgia.

30 Jul 2013

Researchers discover solution to long-standing medical mystery in Huntington's disease

Researchers at McMaster University have discovered a solution to a long-standing medical mystery in Huntington's disease (HD). HD is a brain disease that can affect 1 in about 7,000 people in mid-life, causing an increasing loss of brain cells at the centre of the brain.

30 Jul 2013

Genistein derived from soybeans shows promise in inhibiting HIV infection

A compound found in soybeans may become an effective HIV treatment without the drug resistance issues faced by current therapies, according to new research by George Mason University researchers.

30 Jul 2013

NeuroSigma receives FDA approval to begin Phase III trial of Monarch eTNS System for epilepsy

NeuroSigma, Inc., today announced conditional approval by the U.S. Food and Drug Administration of its Investigational Device Exemption application to commence a Phase III pivotal trial of the Monarch eTNS System for treatment of drug resistant epilepsy.

30 Jul 2013

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis

Anacor Pharmaceuticals announced today that on July 26, 2013 it submitted its New Drug Application to the U.S. Food and Drug Administration for tavaborole, its drug candidate for the topical treatment of onychomycosis. Onychomycosis is a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.

30 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Ligand Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its proprietary Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.

26 Jul 2013

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Takeda Pharmaceutical Company Limited ("Takeda") announced today that it has unblinded the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed during or following chemotherapy based on the recommendation of the Independent Data Monitoring Committee (IDMC).

26 Jul 2013

Elsevier announces winner of first Netter Atlas Medical Illustration Contest

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the winner of the first Netter Atlas Medical Illustration Contest.

26 Jul 2013

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.

26 Jul 2013

EGFR mutation testing dropped once funding from pharmaceutical industry discontinued

Significant advances have taken place in the management of patients with advanced and metastatic non-small-cell lung cancer over the last 5 years. Traditionally, all advanced NSCLC patients were treated in a similar manner.

26 Jul 2013

Study: Daily dietary supplementation with blend of omega fatty acids improves severe dry eye

Study findings published online, ahead of print, in Cornea show that daily dietary supplementation with a unique combination of omega fatty acids (GLA, EPA and DHA) for six months is effective in improving ocular irritation symptoms and halting the progression of inflammation that characterizes moderate to severe dry eye.

25 Jul 2013

Ascendancy Healthcare signs multi-year collaboration with Quintiles

Ascendancy Healthcare, Inc. dedicated to the commercialization of therapeutic products to meet unmet medical needs in China and other high-growth Asian markets, announced today a multi-year collaboration with Quintiles, the world's largest provider of biopharmaceutical development and commercial outsourcing services.

25 Jul 2013

Mylan, Orion sign settlement, license agreement for generic version of STALEVO

Mylan Inc. today confirmed that Mylan Pharmaceuticals Inc. and Orion Corporation have entered into a settlement and license agreement settling the parties litigation in connection with Mylan's filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Carbidopa/Levodopa/Entacapone Tablets, 12.5 mg/50 mg/200 mg, 18.75 mg/75 mg/200 mg, 25 mg/100 mg/200 mg, 31.25 mg/125 mg/200 mg, 37.5 mg/150 mg/200 mg, and 50 mg/200 mg/200 mg.

25 Jul 2013

Contrasting perspectives on e-cigarettes from smoking cessation experts

The increasing popularity and availability of e-cigarettes (otherwise known as Electronic Nicotine Delivery Systems, or ENDS) in many countries has prompted fierce debate among public health professionals, with some expressing concerns that lack of safety information for the devices could result in unforeseen damage to public health if they are not appropriately regulated.

25 Jul 2013

Teva, Lonza decide to discontinue biosimilars collaboration

Teva Pharmaceutical Industries and Lonza Group today announced that following a strategic review of the Teva-Lonza Joint Venture (TL-JV), the companies have decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars.

25 Jul 2013

Study: Docs place 'major responsibility' for health care costs on others

In a survey of doctors by Mayo Clinic researchers, most respondents pointed to lawyers, health insurers, hospitals, drug companies and patients as having a large stake in cutting costs.

25 Jul 2013

Perfluoroalkyl substances are crossing blood brain barrier of polar bears

PerFluoroAlkyl Substances (PFASs) and precursor compounds have been used in a wide variety of commercial and industrial products over the past six decades. Applications include water and oil repellent coatings, e.g. for textiles, paper products, carpets and food packaging, pharmaceuticals and surfactants in cleaning products and fire-fighting foams.

25 Jul 2013

STED-RICS microscopy method records rapid movements of molecules in live samples

The newly developed STED-RICS microscopy method records rapid movements of molecules in live samples. By combining raster image correlation spectroscopy (RICS) with STED fluorescence microscopy, researchers of Karlsruhe Institute of Technology (KIT) opened up new applications in medical research, e.g. analyzing the dynamics of cell membranes at high protein concentrations.

25 Jul 2013

Pharmaceuticals News and Research

NPS MedicineWise finds little or no clinical benefit in switching to rivaroxaban for stroke prevention

FDA grants orphan-drug designation to Convergence's CNV1014802 for treatment of TN

Researchers discover solution to long-standing medical mystery in Huntington's disease

Genistein derived from soybeans shows promise in inhibiting HIV infection

NeuroSigma receives FDA approval to begin Phase III trial of Monarch eTNS System for epilepsy

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Elsevier announces winner of first Netter Atlas Medical Illustration Contest

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

EGFR mutation testing dropped once funding from pharmaceutical industry discontinued

Study: Daily dietary supplementation with blend of omega fatty acids improves severe dry eye

Ascendancy Healthcare signs multi-year collaboration with Quintiles

Mylan, Orion sign settlement, license agreement for generic version of STALEVO

Contrasting perspectives on e-cigarettes from smoking cessation experts

Teva, Lonza decide to discontinue biosimilars collaboration

Study: Docs place 'major responsibility' for health care costs on others

Perfluoroalkyl substances are crossing blood brain barrier of polar bears

STED-RICS microscopy method records rapid movements of molecules in live samples

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence